Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations01:19

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GOLD 2026 COPD ABE assessment tool to identify individuals at high risk in a UK multicentre COPD cohort (ERICA).

BMJ open respiratory research·2026
Same author

Longitudinal <sup>1</sup>H and <sup>129</sup>Xe Lung MRI in Patients With Post-COVID Residual Lung Abnormalities.

Journal of magnetic resonance imaging : JMRI·2026
Same author

Developing a job retention vocational rehabilitation intervention for people with long covid: a person-based approach.

BMJ open·2026
Same author

Where fresh air fails: COPD and the hidden burden of coastal living.

The Lancet. Respiratory medicine·2026
Same author

Incidence of diabetes mellitus following hospitalisation with influenza: a population-based cohort study in England.

BMJ open·2026
Same author

Investigating prognostic classifications of preexisting multiple long-term conditions for health outcomes 1 year after COVID-19 hospitalization: A UK prospective observational study.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same journal

Use of oscillatory positive expiratory pressure (OPEP) devices to augment sputum clearance in COPD: An updated systematic review and meta-analysis.

Chronic respiratory disease·2026
Same journal

Exposure to indoor wood smoke, rather than hypoxemia, is a risk factor for cognitive impairment in COPD patients living at high altitude.

Chronic respiratory disease·2026
Same journal

Post COVID REspiratory mechanisms and the efficacy of a breathing exercise intervention for DYsregulated breathing (Remedy): A feasibility RCT study.

Chronic respiratory disease·2026
Same journal

Diurnal and seasonal variation in six-minute walk distance in pulmonary hypertension: Implications for clinical monitoring.

Chronic respiratory disease·2026
Same journal

Remote behaviour change service for inactive adults with lung disease: A non-randomised controlled study.

Chronic respiratory disease·2026
Same journal

A qualitative study on medication literacy among patients with chronic obstructive pulmonary disease.

Chronic respiratory disease·2026
See all related articles

Related Experiment Video

Updated: May 17, 2026

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Systemic comorbidities in bronchiectasis.

Nichola S Gale1, Charlotte E Bolton, Jamie M Duckers

  • 1Cardio Respiratory Medicine, Wales Heart Research Institute, School of Medicine, Cardiff University, UK.

Chronic Respiratory Disease
|November 7, 2012
PubMed
Summary
This summary is machine-generated.

Patients with bronchiectasis experience increased arterial stiffness, inflammation, and reduced exercise capacity, similar to COPD comorbidities. Further research is needed to manage these associated health risks in bronchiectasis patients.

Related Experiment Videos

Last Updated: May 17, 2026

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Area of Science:

  • Pulmonary Medicine
  • Cardiovascular Health
  • Metabolic Health

Background:

  • Bronchiectasis shares inflammatory pathways with COPD.
  • COPD is associated with cardiovascular disease, bone density loss, and muscle wasting.
  • These comorbidities have not been extensively studied in bronchiectasis.

Purpose of the Study:

  • To investigate if bronchiectasis patients exhibit comorbidities similar to COPD.
  • To compare cardiovascular risk markers, inflammation, body composition, bone mineral density, and exercise capacity between bronchiectasis patients and controls.

Main Methods:

  • A case-control study comparing 20 bronchiectasis patients with 20 healthy controls.
  • Assessments included aortic pulse wave velocity (PWV), blood pressure, inflammatory markers (IL-6), metabolic markers (albumin, glucose, lipids), body composition (FFMI), bone mineral density (BMD), 6-minute walk distance (6MWD), and physical activity levels.

Main Results:

  • Bronchiectasis patients showed increased aortic PWV (arterial stiffness) compared to controls (p < 0.05).
  • Elevated IL-6 and reduced albumin and glucose levels were observed in bronchiectasis patients.
  • Despite similar BMI, FFMI, and mean BMD, fewer bronchiectasis patients had healthy BMD (20% vs 50%).
  • Reduced 6MWD and self-reported physical activity were noted in bronchiectasis patients (p < 0.05).

Conclusions:

  • Bronchiectasis is associated with increased arterial stiffness, systemic inflammation, reduced exercise capacity, and bone thinning.
  • These findings suggest comorbidities similar to COPD in bronchiectasis patients.
  • Further evaluation and management strategies for these comorbidities in bronchiectasis are warranted.